 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Quest Study Finds Sanger-based BRAF Mutation Test More Sensitive than Roche's Cobas Test
June 13, 2012
Quest Study Finds Sanger-based BRAF Mutation Test More Sensitive than Roche's Cobas Test
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- JP Morgan Healthcare Conference, Day Two: Life Technologies, Roche, Agilent, Thermo Fisher, Cepheid, GenMark
January 9, 2013 / GenomeWeb Daily News - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - CHMP Recommends EU Approval of Roche PGx Drug Zelboraf
December 21, 2011 / Pharmacogenomics Reporter - Thomas Jefferson University Hospital Offering Roche's FDA-Approved BRAF Test
November 9, 2011 / Pharmacogenomics Reporter - FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter